-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 14th, the clinical application of Chia Tai Tianqing Pharmaceutical's Class 1 new drug TQB2868 injection was accepted by the CDE and became the second category of this month to declare a clinical Class 1 new drug
Source: CDE official website
From September until now, CP Tianqing Pharmaceuticals has two Class 1 new drugs declared for clinical use, namely TQB2868 injection and TQB2916 injection.
According to data from Minaiwang, since 2021, 15 innovative drugs have been approved for clinical use by Chia Tai Tianqing Pharmaceutical
Chia Tai Tianqing Pharmaceutical has been approved as a new clinical drug since 2021
Source: Meinenet MED2.
13 of the 15 innovative drugs are Class 1 new drugs
From the perspective of development progress, inhalation TQC3721 suspension, TQC2731 injection, TQB3909 tablets, TQB3824 tablets, TQB3823 tablets, TQB3820 tablets, TQB3811 tablets, TQB2858 injections, etc.
It can be seen from the product line of CP Tianqing that now the company’s research and development focus has gradually shifted to the field of anti-tumor.
In June 2019, Chia Tai Tianqing Kangfang, a joint venture between Chia Tai Tianqing Pharmaceuticals and Kangfang Biological, was established, dedicated to the research and development of the PD-1 antibody drug AK105 project; in August 2021, Paraprizumab injection was approved for listing , CP Tianqing Pharmaceutical officially entered the battlefield of PD-1 filled with gunpowder
Throughout the development history of Chia Tai Tianqing Pharmaceutical, the company initially positioned liver disease drugs as the main research and development area, accumulated the first pot of gold for enterprise development, and gradually formed an independent research and development system, and then continued to expand The product line of research and development has now embarked on a characteristic development path that belongs to Chia Tai Tianqing Pharmaceutical Co.
Source: Mi Nei.
